立体定向消融放疗综合治疗寡转移/进展的单次与多次分割试验
立体定向消融放疗综合治疗寡转移/进展的单次与多次分次非劣效性试验:SIMPLIFY-SABR-COMET
Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques, while trying to avoid healthy tissues and organs. However, SABR treatment requires increased planning, treatment time, cost and potential for higher toxicity due to the higher dose. The purpose of this study is to compare single fraction (SF) SABR vs. multiple fraction (MF) SABR in regards to toxicities, progression-free survival, quality of life (QoL), and cost-effectiveness. In a subset of patients, we will also compare patient QoL, hospitalization rates, and cost-effectiveness between patients who complete QoL questionnaires, record symptoms and receive healthcare provider-guided intervention vs. patients who complete QoL questionnaires only.
研究概览
地位
详细说明
Radiation can be delivered in multiple fractions, or doses, and can take up to several weeks or months of treatment depending on the type of cancer. Radiation can also be offered in a single fraction. Both techniques have evidence for use in clinical care. Multiple fraction is offered to reduce the amount of radiation given at a single time that could reduce late toxicities. However, single fraction radiotherapy is more cost-effective and saves patient time. With this trial, we will compare single fraction vs. multiple fraction in regards to their impact on toxicity, progression-free survival: time from randomization to disease progression at any site or death, lesional control rate: lesion size post-SABR, quality of life and cost-effectiveness.
In a subset of sites, we will also investigate the impact of healthcare-provider guided intervention on quality of life. Questionnaires capture various symptoms such as pain, fatigue and information relating to physical, social, and mental wellbeing. This information can help shed light on patient experience and provide a better understanding of the effects of radiation therapy. In this trial, we will compare quality of life questionnaire completion, symptom reporting and healthcare-provider guided intervention vs. quality of life questionnaire completion alone, in regards to patient quality of life. Hospitalization rates and frequency of emergency department visits will also be investigated.
Sample size: The total sample size of 598 for this trial was calculated based on the primary endpoint of toxicity for the single vs. multiple fraction SABR randomization. Calculations were performed based on the results of the SABR-5 trial and our clinical judgement.
Quality Assurance: Radiation treatments are based on the current phase III SABR-COMET-3 trial and as per recent clinical evidence. All treatments will be planned as per protocol including computed tomography (CT) simulation, organs at risk contouring and undergo a quality assurance process.
For the subset of sites involved in the second randomization, training will be provided to patients on the use of Noona, a patient-reported outcome platform.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Robert Olson, MD, MSC, FRCPC
- 电话号码:250-645-7300
- 邮箱:rolson2@bccancer.bc.ca
研究联系人备份
- 姓名:Hadassah Abraham, MSc
- 电话号码:250-645-7300
- 邮箱:hadassah.abraham@bccancer.bc.ca
学习地点
-
-
British Columbia
-
Kelowna、British Columbia、加拿大
- 招聘中
- BC Cancer
-
接触:
- Benjamin Mou, MD
- 电话号码:250-712-3900
- 邮箱:benjamin.mou@bccancer.bc.ca
-
Prince George、British Columbia、加拿大、V2M 7E9
- 招聘中
- BC Cancer
-
接触:
- Robert A Olson, MD
- 电话号码:2506457300
- 邮箱:rolson2@bccancer.bc.ca
-
接触:
- Hadassah Abraham
- 电话号码:2506457300
- 邮箱:hadassah.abraham@bccancer.bc.ca
-
首席研究员:
- Robert A Olson
-
Surrey、British Columbia、加拿大
- 招聘中
- BC Cancer
-
接触:
- Devin Schellenberg, MD
- 电话号码:604-930-2098
- 邮箱:dschellenberg@bccancer.bc.ca
-
Vancouver、British Columbia、加拿大
- 招聘中
- BC Cancer
-
接触:
- Mitchell Liu, MD
- 电话号码:6048776000
- 邮箱:mliu@bccancer.bc.ca
-
Victoria、British Columbia、加拿大
- 尚未招聘
- BC Cancer - Victoria
-
接触:
- Boris Valev, MD
- 电话号码:250-519-5500
- 邮箱:boris.valev@bccancer.bc.ca
-
-
Ontario
-
Greater Sudbury、Ontario、加拿大、P3E 5J1
- 招聘中
- Health Sciences North Research Institute
-
首席研究员:
- Andrew Pearce
-
接触:
- Jessica Richer
- 电话号码:1922 705.522.6237
- 邮箱:jricher@hsnri.ca
-
Toronto、Ontario、加拿大、M5G 1X6
- 招聘中
- Princess Margaret Cancer Centre | University Health Network
-
首席研究员:
- Chiaojung Jillian Tsai
-
接触:
- Yoona Shin
- 电话号码:416-946-4558
- 邮箱:yoona.shin@uhn.ca
-
-
-
-
Connacht
-
Galway、Connacht、爱尔兰、H91 YR71
- 招聘中
- University Hospital Galway
-
接触:
- Helen McLoughlin
- 电话号码:091 542600
- 邮箱:Helen.McLoughlin6@hse.ie
-
首席研究员:
- Ronan McDermott
-
-
Dublin
-
Dublin、Dublin、爱尔兰、D06 E1C9
- 招聘中
- St. Luke's Radiation Oncology Network
-
接触:
- Roisin O'Maolalai
- 电话号码:0035314065458
- 邮箱:roisin.omaolalai@slh.ie
-
首席研究员:
- Lorna Keenan
-
-
Leinster
-
Dublin、Leinster、爱尔兰、D18 AK68
- 招聘中
- Beacon Hospital
-
接触:
- Roisin Conaty
- 电话号码:353 1 293 6600
- 邮箱:roisin.conaty@beaconhospital.ie
-
首席研究员:
- Alina Mihai
-
Dublin、Leinster、爱尔兰、D07 WKW8
- 招聘中
- Mater Private Hospital
-
接触:
- Lisa Scahill
- 电话号码:+353 (1) 8034831
- 邮箱:lscahill@mater.ie
-
首席研究员:
- Daniel Cagney
-
-
Munster
-
Cork、Munster、爱尔兰、T12 DV56
- 招聘中
- Bon Secours Radiotherapy Cork in Partnership with UPMC Hillman Cancer Centre
-
首席研究员:
- Paul Kelly
-
接触:
- Erica Bennett
- 电话号码:+353 21-486-11
- 邮箱:bennette10@upmc.ie
-
Cork、Munster、爱尔兰、T12 DC4A
- 招聘中
- Cork University Hospital
-
接触:
- Murtaza Gangardiwala
- 电话号码:021 4234807
- 邮箱:murtaza.gangardiwala@hse.ie
-
首席研究员:
- Aisling Barry
-
Waterford、Munster、爱尔兰、X91 DH9W
- 招聘中
- UPMC Whitfield Hospital - Waterford
-
接触:
- Erica Bennett
- 邮箱:bennette10@upmc.ie
-
首席研究员:
- Ciara Lyons
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
1-5 current oligometastatic or oligo-progressive lesions
-
Age 18 years or older
-
Able to provide informed consent
-
Able to complete electronic entry of patient reported outcomes and questionnaires independently or with assistance from a caregiver/family/friend/research staff using electronic methods after providing consent to email use.
-
Life expectancy > 6 months
-
Histologically confirmed malignancy with metastatic disease detected on imaging. Biopsy of metastasis is preferred, but not required.
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
-
Controlled primary tumor: defined as at least 3 months since original tumor treated radically, with no progression at primary site (can be considered controlled if no evidence of the primary tumour on imaging [e.g. primary unknown])
-
A history including ECOG performance status, performed within 6 weeks prior to enrollment
-
Patient has had a CT chest, abdomen and pelvis or PET-CT within 10 weeks prior to enrollment, and within 13 weeks prior to treatment
-
Patient has had a nuclear bone scan (if no positron emission tomography-computed tomography [PET-CT]) within 10 weeks prior to enrollment, and within 13 weeks prior to treatment
-
Patient has had CT or MRI brain imaging if primary has a propensity for central nervous system metastases (if deemed appropriate by the treating investigator) within 10 weeks prior to enrollment, and within 13 weeks prior to treatment.
-
For patients with known spine metastases, patient has had MRI spine imaging within 10 weeks prior to enrollment, and with 13 weeks prior to treatment.
-
If solitary lung nodule for which biopsy is unsuccessful or not possible, patient has had an FDG (fluorodeoxyglucose) PET scan or CT (chest, abdomen, pelvis) and bone scan within 10 weeks prior to enrollment, and within 13 weeks prior to treatment
-
If colorectal primary with rising Carcinoembryonic antigen (CEA), but equivocal imaging, patient has had an FDG PET scan within 10 weeks prior to enrollment, and within 13 weeks prior to treatment
-
Patient is judged able to:
- Maintain a stable position during therapy
- Tolerate immobilization device(s) that may be required to deliver SABR safely
-
Negative pregnancy test for People of Child-Bearing Potential (POCBP) within 4 weeks of RT start date
Exclusion Criteria:
-
Uncontrolled concurrent malignant cancer
-
Lesion in femoral bone requiring surgical fixation
-
No chemotherapy agents (cytotoxic, or molecularly targeted agents) will be used within the period of time commencing 1 week prior to radiation, lasting until 1 week after the last fraction. See section 5.3.3 regarding this criterion.
-
Serious medical comorbidities precluding radiotherapy. These include interstitial lung disease in patients requiring thoracic radiation, Crohn's disease in patients where the gastrointestinal (GI) tract will receive radiotherapy, and connective tissue disorders such as lupus or scleroderma.
-
Substantial overlap with a previously treated radiation volume. Prior radiotherapy in general is allowed, as long as the composite plan meets dose constraints herein. For patients treated with radiation previously, similar biological effective dose calculations should be used to equate previous doses to the tolerance doses listed below. All such cases should be discussed with the local and study principal investigators (PIs).
-
Current malignant pleural effusion
-
Liver metastases located in the "Biliary no fly zone" defined for this trial as common biliary track, cystic duct and distal branches (1 cm) + 5 mm.
-
Inability to treat all sites of oligometastatic or oligoprogressive disease (all lesions must be suitable for both single- and multi-fraction SABR)
-
Presence of brain metastases as the sole site of disease
-
Maximum size of 5 cm for lesions outside the brain, except:
- Bone metastases over 5 cm may be included, if in the opinion of the local PI it can be treated safely (e.g. rib, scapula, pelvis)
-
Any brain metastasis > 3.5 cm in size or a total volume of brain metastases greater than 30 cc is excluded
-
Clinical or radiologic evidence of spinal cord compression. Patients can be eligible if surgical resection has been performed
-
Patients with spine instability as judged by a Spinal Instability Neoplastic Score (SINS) of >12
-
Dominant brain metastasis requiring surgical decompression
-
Surgical resection of all metastases (i.e. no lesion available to be treated with SABR)
-
Complete response to systemic therapy, defined as the absence of visible disease on imaging
-
Pregnant or breast feeding
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:阶乘赋值
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Multiple fraction SABR (Arm 1)
Participants randomized to this arm will receive multiple fraction SABR |
Participants randomized to this arm will receive MF SABR: Dose/Fractionation are as follows: Lung: Greater than 2 cm from mediastinum or brachial plexus or if mandatory organ-at-risk (OAR) constraints are met: 48 Gy in 4 fractions (12 Gy/#), 54 Gy in 3 fractions (18 Gy/#), daily or every second day Lung: Within 2 cm of mediastinum or brachial plexus 60 Gy in 8 fractions (7.5 Gy/#), 50 Gy in 5 fractions (10 Gy/#), daily Bone: Any bone except spine: 35 Gy in 5 fractions (7 Gy/#), daily Liver: 54 Gy in 3 fractions (18 Gy/#) or 5 fractions (10.8 Gy/#), daily or every second day Spine: 24 Gy in 2 fractions (12 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily Adrenal: 40 Gy in 5 fractions (8 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily Lymph node/soft tissue: 40 Gy in 5 fractions (8 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily Brain - dose per institutional policy for stereotactic lesions (no whole brain RT). |
|
实验性的:Single fraction SABR (Arm 2)
Participants randomized to this arm will receive single fraction SABR |
Participants randomized to this arm will receive SF SABR Treatment recommendations are as follows: Lung: Greater than 2 cm from mediastinum or brachial plexus or if mandatory OAR constraints are met: 30 Gy in 1 fraction Lung: Within 2 cm of mediastinum or brachial plexus 20 Gy in 1 fraction Bone, Spine, Adrenal, lymph node/soft tissue: 20 Gy in 1 fraction Liver: 30 Gy in 1 fraction Brain: dose as per institutional policy |
|
有源比较器:Patient-reported outcome (PRO) collection : QoL reporting alone (Arm A)
Participants will complete the EuroQoL-5Dimensions-5levels (EQ-5D-5L) and Functional Assessment of Cancer Therapy-General (FACT-G) prior to each scheduled follow-up (FU). |
Participants randomized to this arm will complete the EQ-5D-5L and FACT-G at baseline and each follow-up visit |
|
实验性的:QoL reporting and healthcare provider (HCP) intervention guided by symptom screen (Arm B)
|
Participants randomized to this arm will complete the FACT,G, EQ-5D-5L, radiation-symptom screen and receive healthcare provider-guided intervention based on their symptom reports. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Adverse events
大体时间:At 6 weeks, 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months
|
Occurrences and changes in grade 3 or higher adverse events related to treatment, according to CTCAE v5.0 |
At 6 weeks, 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months
|
|
Change in patient-reported quality of life
大体时间:At 6 weeks, 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months
|
As measured by the EQ-5D-5L. This questionnaire provides measures for mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. It also includes a numbered scale from 0 to 100 where 100 means the best health one can imagine, and 0 means the worst health one can imagine. |
At 6 weeks, 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Lesional control rate
大体时间:At 6 weeks, 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months
|
Rate is determined based on lesion size post-SABR using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 |
At 6 weeks, 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months
|
|
Progression-free survival
大体时间:At 6 weeks, 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months
|
Time from randomization to disease progression at any site or death |
At 6 weeks, 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months
|
|
Overall survival
大体时间:Approximately at the end of year 5 of follow-up, at study completion
|
Time from randomization to death from any cause (exploratory) |
Approximately at the end of year 5 of follow-up, at study completion
|
|
Resource utilization
大体时间:At 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months
|
Assessed via patient- and provider-reported hospitalization rates, frequency of emergency department visits, number of patients with systemic or radiation therapy post SABR treatment on trial |
At 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months
|
合作者和调查者
赞助
调查人员
- 首席研究员:Robert Olson, MD, MSc, FRCPC、BC Cancer - Prince George
出版物和有用的链接
一般刊物
- Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011 Dec;20(10):1727-36. doi: 10.1007/s11136-011-9903-x. Epub 2011 Apr 9.
- Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995 Jan;13(1):8-10. doi: 10.1200/JCO.1995.13.1.8. No abstract available.
- Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993 Mar;11(3):570-9. doi: 10.1200/JCO.1993.11.3.570.
- Cox BW, Spratt DE, Lovelock M, Bilsky MH, Lis E, Ryu S, Sheehan J, Gerszten PC, Chang E, Gibbs I, Soltys S, Sahgal A, Deasy J, Flickinger J, Quader M, Mindea S, Yamada Y. International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e597-605. doi: 10.1016/j.ijrobp.2012.03.009. Epub 2012 May 19.
- Olson R, Mathews L, Liu M, Schellenberg D, Mou B, Berrang T, Harrow S, Correa RJM, Bhat V, Pai H, Mohamed I, Miller S, Schneiders F, Laba J, Wilke D, Senthi S, Louie AV, Swaminath A, Chalmers A, Gaede S, Warner A, de Gruijl TD, Allan A, Palma DA. Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial. BMC Cancer. 2020 May 5;20(1):380. doi: 10.1186/s12885-020-06876-4.
- Patel PH, Palma D, McDonald F, Tree AC. The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively? Clin Oncol (R Coll Radiol). 2019 Dec;31(12):824-833. doi: 10.1016/j.clon.2019.05.015. Epub 2019 Jun 8.
- Nguyen TK, Chin L, Sahgal A, Dagan R, Eppinga W, Guckenberger M, Kim JH, Lo SS, Redmond KJ, Siva S, Stish BJ, Chan R, Lawrence L, Lau A, Tseng CL. International Multi-institutional Patterns of Contouring Practice and Clinical Target Volume Recommendations for Stereotactic Body Radiation Therapy for Non-Spine Bone Metastases. Int J Radiat Oncol Biol Phys. 2022 Feb 1;112(2):351-360. doi: 10.1016/j.ijrobp.2021.09.004. Epub 2021 Sep 9.
- Redmond KJ, Robertson S, Lo SS, Soltys SG, Ryu S, McNutt T, Chao ST, Yamada Y, Ghia A, Chang EL, Sheehan J, Sahgal A. Consensus Contouring Guidelines for Postoperative Stereotactic Body Radiation Therapy for Metastatic Solid Tumor Malignancies to the Spine. Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):64-74. doi: 10.1016/j.ijrobp.2016.09.014. Epub 2016 Sep 17.
- Dunne EM, Sahgal A, Lo SS, Bergman A, Kosztyla R, Dea N, Chang EL, Chang UK, Chao ST, Faruqi S, Ghia AJ, Redmond KJ, Soltys SG, Liu MC. International consensus recommendations for target volume delineation specific to sacral metastases and spinal stereotactic body radiation therapy (SBRT). Radiother Oncol. 2020 Apr;145:21-29. doi: 10.1016/j.radonc.2019.11.026. Epub 2019 Dec 23.
- Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014 Sep 29;106(9):dju244. doi: 10.1093/jnci/dju244. Print 2014 Sep.
- Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. J Clin Oncol. 2016 Feb 20;34(6):557-65. doi: 10.1200/JCO.2015.63.0830. Epub 2015 Dec 7.
- Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017
- Olson R, Abraham H, Leclerc C, Benny A, Baker S, Matthews Q, Chng N, Bergman A, Mou B, Dunne EM, Schellenberg D, Jiang W, Chan E, Atrchian S, Lefresne S, Carolan H, Valev B, Tyldesley S, Bang A, Berrang T, Clark H, Hsu F, Louie AV, Warner A, Palma DA, Howell D, Barry A, Dawson L, Grendarova P, Walker D, Sinha R, Tsai J, Bahig H, Thibault I, Koul R, Senthi S, Phillips I, Grose D, Kelly P, Armstrong J, McDermott R, Johnstone C, Vasan S, Aherne N, Harrow S, Liu M. Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET. BMC Cancer. 2024 Feb 3;24(1):171. doi: 10.1186/s12885-024-11905-7.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- SIMPLIFY-SABR-COMET
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.